GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Co-Diagnostics Inc (NAS:CODX) » Definitions » Total Inventories

Co-Diagnostics (Co-Diagnostics) Total Inventories : $1.67 Mil (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Co-Diagnostics Total Inventories?

Co-Diagnostics's total inventories for the quarter that ended in Dec. 2023 was $1.67 Mil. Co-Diagnostics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $3.09 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Co-Diagnostics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $1.61.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Co-Diagnostics's Days Inventory for the three months ended in Dec. 2023 was 95.08.

Inventory Turnover measures how fast the company turns over its inventory within a year. Co-Diagnostics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.96.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Co-Diagnostics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.87.


Co-Diagnostics Total Inventories Historical Data

The historical data trend for Co-Diagnostics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Co-Diagnostics Total Inventories Chart

Co-Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only 0.20 8.00 2.00 5.31 1.67

Co-Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 5.30 4.69 4.52 1.67

Co-Diagnostics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Co-Diagnostics  (NAS:CODX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Co-Diagnostics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(58.548+0.75 * 0.304+0.5 * 1.665-9.307
-0-0)/31.2597
=1.61

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Co-Diagnostics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=3.0925/2.968*365 / 4
=95.08

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Co-Diagnostics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=2.968 / 3.0925
=0.96

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Co-Diagnostics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=3.0925 / 3.555
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Co-Diagnostics Total Inventories Related Terms

Thank you for viewing the detailed overview of Co-Diagnostics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Co-Diagnostics (Co-Diagnostics) Business Description

Traded in Other Exchanges
Address
2401 South Foothill Drive, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
Executives
Brian Lee Brown officer: Chief Financial Officer 5322 W. BRIAR PARK ROAD, HERRIMAN UT 84096
Ted Murphy director 64 INDUSTRIAL RD., RICHMOND HILL A6 L4C2Y1
Eugene Durenard director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Dwight H Egan director, officer: CEO and President 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Richard S Serbin director 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
James B Nelson director 26 WEST MISSION AVENUE, SUITE 8, SANTA BARBARA CA 93010
Reed L Benson officer: CFO and Secretary 7050 UNION PARK CENTER, #600, SALT LAKE CITY UT 84047
Edward L. Murphy director 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT 84109
Brent Satterfield director, officer: Chief Science Officer 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
America 2030 Capital, Llc 10 percent owner 1301 SHILOH RD., NW, SUITE 1231, KENNESAW GA 30144
Edward Borkowski director 1500 CORPORATE DRIVE, SUITE 400, CANONSBURG PA 15317
Frank J Kiesner director 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124
Reagents, Llc 10 percent owner 8160 S. HIGHLAND DR, SANDY UT 84093
Legends Capital Group, Llc 10 percent owner 4049 S. HIGHLAND DRIVE, SALT LAKE CITY UT 84124